IBM’s Two-Front War: A Quantum Acquisition Meets a Mainframe Meltdown
Published on 07/25/2026 at 22:50 | Redaktion boerse-global.de
The numbers tell a story of whiplash. IBM shares closed Friday at €188.38, up 3.74% on the day — a welcome bounce after one of the most brutal stretches in the company’s history. But that single-day gain barely registers against a 27.52% year-to-date decline and an 18.63% monthly rout. The stock now sits 35.67% below its 52-week high of €292.85, reached in early June, and just 7.56% above the 52-week low of €175.14 touched on July 23.
That low came just one day after the company signed a binding agreement to acquire HRL Laboratories, a quantum research institute previously co-owned by Boeing and General Motors. The timing was deliberate. On July 22, IBM had already slashed its full-year 2026 revenue growth forecast to a range of 4% to 5%, down from above 5%, citing a disastrous second quarter that missed both top- and bottom-line expectations.
The Mainframe Collapse That Broke the Narrative
The damage is concentrated in a single, painful spot. Revenue from IBM’s Z-mainframes — the workhorses processing millions of daily transactions for banks and airlines — cratered 42% in the second quarter. That single segment dragged the entire infrastructure unit down 7% to $3.84 billion. CFO James Kavanaugh put it bluntly: the decline in mainframe hardware and transaction software clipped IBM’s quarterly growth by more than five percentage points.
The root cause, as Reuters reported, is a structural shift: companies are reallocating IT budgets toward AI data centers at the expense of traditional software and mainframe spending. CEO Arvind Krishna acknowledged in a shareholder letter that the quarter’s execution simply didn’t work — a rare admission that rarely goes unpunished.
Should investors sell immediately? Or is it worth buying IBM?
Yet not every reading of the numbers was bleak. CFRA analyst Brooks Idlet argued that the broader software sector actually looked better after IBM’s report, since the company’s software issues were specifically hardware-related, as management itself laid out. The software segment held up with solid growth even as infrastructure cratered.
A Quantum Bet Against the Clock
Enter HRL Laboratories. The acquisition, expected to close by the end of the third quarter of 2026 pending regulatory approvals, brings IBM silicon-spin-qubit expertise that complements its existing roadmap for superconducting quantum computers. Combined with the Anderon quantum wafer foundry launched in May, IBM now has a dual-pronged strategy toward fault-tolerant quantum systems.
The deal also signals that key customers remain engaged. Boeing and GM plan to continue working with IBM on quantum applications after the transaction closes — a tangible vote of confidence.
But the clock is ticking. The question for investors is whether IBM’s high-margin software business, together with this nascent quantum push, can grow fast enough to offset the structural decline in mainframes and stagnation in consulting. If the acceleration works, the stock could decouple from its old hardware-cycle valuation. If it doesn’t, the pressure will persist.
The Analyst Divide: No One Has Conviction
Wall Street is split — and that split itself is telling. Some firms cut ratings and price targets after the report, citing valuation risks relative to the sector. Others raised their targets despite the missed expectations, arguing the sell-off was overdone. This division reflects a deeper uncertainty: is this a one-time execution misstep tied to mainframe timing, or the start of a structural re-rating as AI infrastructure spending cannibalizes legacy hardware and software budgets?
The average analyst price target stands at €231.06, implying 22.7% upside from current levels. Even after the guidance cut, the analyst community still prices in a meaningful recovery scenario. But that’s a different claim from saying the worst is over.
Technical Signals: Overbought in Pain, Oversold in Hope
The RSI of 35.5 signals an oversold stock, a zone where short-term bounces become statistically more likely regardless of the fundamental debate. But an oversold RSI is a timing signal, not a judgment on fundamentals. It doesn’t change the fact that guidance was cut, not raised.
The technical picture remains bearish. The stock trades 19.44% below its 200-day moving average of €233.84 and 17.61% below the 50-day average of €228.64 — a classic setup that typically chokes off rallies early. The annualized 30-day volatility of nearly 85% underscores persistent market jitters.
IBM at a turning point? This analysis reveals what investors need to know now.
Institutional investors are showing caution. Unisphere Establishment and the Bank of Nova Scotia trimmed their IBM positions in the first quarter by 13.1% and 29.2%, respectively — a sign that at least some large holders are losing patience with the long lead time to meaningful quantum and AI revenue.
What Comes Next
For now, the 52-week low of €175.14 serves as a support level. As long as it holds, the stock is likely in a consolidation phase as the market digests the lowered growth forecast. The next concrete milestone is the HRL acquisition closing by the end of the third quarter, along with any regulatory updates. Equally critical is the distance to the 50-day moving average of €228.64. If that gap persists, Friday’s bounce may prove to be nothing more than a technical countermove within a larger downtrend.
The bull case rests on the idea that the correction has created an attractive entry point, with the oversold RSI and analyst price targets suggesting a floor. The bear case counters that the core business is eroding faster than new ventures can replace it, and that heavy investment in quantum research and the Anderon foundry will weigh on cash flow before those technologies become commercially viable.
One thing is clear: IBM is fighting a two-front war — shoring up a collapsing legacy business while betting billions on a future that may be years away. The market is still deciding which front will win.
Ad
IBM Stock: New Analysis - 25 July
Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
